08:00 , Feb 29, 2016 |  BC Week In Review  |  Clinical News

AMG 319: Phase II started

Cancer Research UK (London, U.K.) began a double-blind, placebo-controlled, U.K. Phase II trial to evaluate 400 mg oral AMG 319 once daily for 21-30 days prior to resection in up to 54 patients. Cancer Research...
07:00 , Jun 26, 2014 |  BC Innovations  |  Targets & Mechanisms

PI3K inhibition: solid immunotherapy

Until now, inhibition of phosphoinositide 3-kinase-d in cancer has been limited to leukemias and lymphomas because the isoform is only expressed on immune cells. A new finding that links the kinase to T cell responses...
07:00 , Sep 6, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Inflammation

Indication Target/marker/pathway Summary Licensing status Publication and contact information Inflammation Inflammation Phosphoinositide 3-kinase-b (PI3Kb); PI3Kd Rat studies identified a pyrrolo pyridine analog as a dual inhibitor of PI3Kb and PI3Kd that could help treat inflammation....
07:00 , May 24, 2012 |  BC Innovations  |  Targets & Mechanisms

Getting selective for gamma

Cellzome AG and Exelixis Inc. have independently designed the first highly selective inhibitors of the g-isoform of phosphoinositide 3-kinase . 1,2 Exelixis plans to out-license its inhibitors, whereas last week's acquisition of Cellzome by GlaxoSmithKline...
08:00 , Feb 27, 2012 |  BioCentury  |  Product Development

Take your PI(3)K

Questions remain about the optimal selectivity profiles for PI3K inhibitors, but big biopharmas are already making their bets. The shift from interesting science to investable compounds - about two decades in the making - hinged...
08:00 , Jan 30, 2012 |  BioCentury  |  Strategy

Amgen swallows BiTEs

Amgen Inc. has been interested in acquiring Micromet Inc. for a long time, and finally got the biotech to agree, six months after the companies tested the waters with a discovery and development deal using...